N-(dimethylphenyl)-2-[1-(pyridin-2-yl)ethylidene]hydrazine-1-carbothioamide as liver cancer HepG2 cell proliferation inhibitors

MD4949C1Active Publication Date: 2026-08-31RADACINI WINES SRL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MD20240037
Authority / Receiving Office
MD · MD
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-11-01
Publication Date
2026-08-31
Estimated Expiration
2044-11-01
Patent Text Reader

Abstract

The invention relates to chemistry and medicine, in particular to biologically active organic compounds of the class of carbothioamides that can be used as liver cancer HepG2 cell proliferation inhibitors and can find application in medicine as precursors of cytostatic preparations for the prophylaxis and treatment of liver cancer.According to the invention, proposed are as liver cancer HepG2 cell proliferation inhibitors the compounds N-(3,4-dimethylphenyl)-2-[1-(pyridin-2-yl)ethylidene]hydrazine-1-carbothioamide (I), N-(2,3-dimethylphenyl)-2-[1-(pyridin-2-yl)ethylidene]hydrazine-1-carbothioamide (II) and N-(3,5-dimethylphenyl)-2-[1-(pyridin-2-yl)ethylidene]hydrazine-1-carbothioamide (III) of the general formula:I: R1= R4= H, R2= R3= CH3; II: R1= R2= H, R3= R4= CH3;III: R1= R3= CH3 ,R2= R4= H.The said compounds expand the arsenal of liver cancer HepG2 cell inhibitors, with high biological activity.
Need to check novelty before this filing date? Find Prior Art